Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.

MLA

Dudek, Arkadiusz Z., et al. “Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 38, no. 11, Apr. 2020, pp. 1138–45. EBSCOhost, https://doi.org/10.1200/JCO.19.02394.

APA

Dudek, A. Z., Liu, L. C., Gupta, S., Logan, T. F., Singer, E. A., Joshi, M., Zakharia, Y. N., Lang, J. M., Schwarz, J. K., Al-Janadi, A., & Alva, A. S. (2020). Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 38(11), 1138–1145. https://doi.org/10.1200/JCO.19.02394

Chicago

Dudek, Arkadiusz Z, Li C Liu, Shilpa Gupta, Theodore F Logan, Eric A Singer, Monika Joshi, Yousef N Zakharia, et al. 2020. “Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 38 (11): 1138–45. doi:10.1200/JCO.19.02394.